Bio Line Rx Ltd. BLRX
We take great care to ensure that the data presented and summarized in this overview for BioLineRx Ltd. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BLRX
View all-
Highbridge Capital Management LLC New York, NY1.01MShares$2.91 Million0.05% of portfolio
-
Cvi Holdings, LLC Wilmington, DE816KShares$2.35 Million4.05% of portfolio
-
Values First Advisors, Inc.166KShares$479,3730.02% of portfolio
-
Atria Wealth Solutions, Inc. New York, NY94.1KShares$271,1030.0% of portfolio
-
Lpl Financial LLC Fort Mill, SC92KShares$264,9600.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA87.2KShares$251,1790.0% of portfolio
-
Morgan Stanley New York, NY79.1KShares$227,8130.0% of portfolio
-
Orin Green Financial, LLC51KShares$146,8800.0% of portfolio
-
Geode Capital Management, LLC Boston, MA40KShares$115,1790.0% of portfolio
-
Two Sigma Securities, LLC New York, NY35.3KShares$101,6920.0% of portfolio
Latest Institutional Activity in BLRX
Top Purchases
Top Sells
About BLRX
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Insider Transactions at BLRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |